Jonathan Corren

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Chronic Obstructive Pulmonary Disease

Intensive Care Unit

Allergic Rhinitis

Top Venues

Journal of asthma and allergy

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

This page only lists publications with an associated author ORCID identifier.

Publications

Reynold A Panettieri, Njira L Lugogo, Jonathan Corren, Christopher S Ambrose
Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types. Journal of asthma and allergy 17 (2024)
Reynold A Panettieri, Njira L Lugogo, Jonathan Corren, Christopher S Ambrose
Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types. Journal of asthma and allergy 17 (2024)
Jonathan Corren, Nicola A Hanania, William W Busse, Lawrence D Sher, Arman Altincatal, Megan Hardin, Leda P Mannent, Nikhil Amin, David J Lederer, Xavier Soler, Juby A Jacob-Nara, Paul J Rowe, Yamo Deniz
Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitization. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2023)
Ian Douglas Pavord, Arnaud Bourdin, Alberto Papi, Christian Domingo Ribas, Jonathan Corren, Arman Altincatal, Amr Radwan, Nami Pandit, Juby Anne Jacob-Nara, Yamo Deniz, Paul J Rowe, Elizabeth Laws, David J Lederer, Megan Hardin
Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of ICS dose. Allergy (2023)
Jonathan Corren, Christopher S Ambrose, Janet M Griffiths, Åsa Hellqvist, Andrew W Lindsley, Jean-Pierre Llanos, Gene Colice, Andrew Menzies-Gow
Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR study. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2022)